CONSENSUS REPORT| SEPTEMBER 23 2022
Diabetes care
Enlace artículo:
10.2337/dci22-0034/147671/Management-of-Hyperglycemia-in-Type-2-Diabetes
Diapositivas:
The Lancet
February 17, 2022
JAMA Clinical Guidelines Synopsis
July 11, 2022
Major recommendations
Diet, physical activity, and behavioral therapy should be designed to achieve and maintain at least 5% weight loss. Additional weight loss usually results in further improvements in control of diabetes and cardiovascular risk (level of evidence B).
Interventions to achieve weight loss should include a high frequency of counseling (≥16 sessions in 6 months) to achieve a 500- to 750-kcal/d energy deficit (level of evidence A).
Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.
Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro
Diabetes Care 2021 July 12
June 25, 2021
DOI: 10.1056/NEJMoa2107519
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.
Julian W Sacre, Dianna J Magliano, Jonathan E Shaw
Diabetes & Metabolism 2021 March 17, : 101249
